over-the-last
Home » Archives for over-the-last
Ziopharm Oncology: Place Your Bets
Friday, August 27th, 2010
Wall Street Teacher submits: Ziopharm Oncology ( ZIOP ): Update Recent price: $3.50 Shares Outstanding: Approx.
Posted in: Pharma News | 0 Comments »
Read the full story
NuPathe’s price cut shows slow biotech IPO recovery
Friday, August 6th, 2010
Conshohocken, PA-based NuPathe has cuts its IPO price to just $10 a share, the company announced today. NuPathe was hoping to raise between $14 and $16 per share for a total of $75 million
Posted in: Pharma News | 0 Comments »
Read the full story
Web first place people go for health information. But you knew that already didn’t you?
Wednesday, July 21st, 2010
Some interesting data from eMarketer this morning. The first tidbit was that the first place people go for health information is the Internet.
Posted in: DTC | 0 Comments »
Read the full story
The fastest growing therapeutic drug classes
Thursday, July 15th, 2010
Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five
Posted in: Pharma News | 0 Comments »
Read the full story
Venrock gets lean and mean with $350M venture fund
Wednesday, July 7th, 2010
Smaller and more tightly focused will be the style for Venrock Associates’ new fund.
Posted in: Pharma News | 0 Comments »
Read the full story
Lilly CEO outlines deal strategy to beef up its pipeline
Tuesday, July 6th, 2010
Eli Lilly CEO John Lechleiter has been making the rounds with financial journalists over the last few days, stressing that the pharma company will bet its future on a new round of deals with biotechs
Posted in: Pharma News | 0 Comments »
Read the full story
Abbott Labs: Growth Stock With an Attractive Yield
Monday, July 5th, 2010
Avi Morris submits: Most of the remaining 43 S&P 500 Dividend Aristocrats have strong finances and are worthy of consideration for value investors, especially those who want to upgrade dividend yields. For example, the stock of Abbott ( ABT ), long time Dividend Aristocrat, has been flattish over the last 10 years, mostly in the 40s & 50s. Friday it closed at $46.46 with a yield of 3.8%
Posted in: Pharma News | 0 Comments »
Read the full story
Johnson & Johnson Product Shortage To Last All Year
Thursday, June 24th, 2010
In an attempt to bury bad news late in the day, Johnson & Johnson this evening released a brief statement saying it does not anticipate having any supplies of the various pediatric over-the-counter medicines that were made its Fort Washington, Pa., plant. The facility, you may recall, was recently shutdown amid FDA scrutiny of various quality-control problems and a subsequent Congressional investigation (background here , here , here and here ). The healthcare giant’s McNeil Consumer Healthcare unit doesn’t expect most of the meds, which include Tylenol and Motrin for youngsters, to become available before the end of the 2010
Posted in: Pharma News | 0 Comments »
Read the full story
Genmab CEO Drakeman bows out of the weakened biotech
Tuesday, June 15th, 2010
A day after Genmab’s battered stock spiked following renewed rumors of a GlaxoSmithKline takeover , the American CEO of the Danish biotech stood down from the helm and was replaced by the developer’s chief scientific officer.
Posted in: Pharma News | 0 Comments »
Read the full story
The Case for Pfizer
Friday, June 11th, 2010
Bret Jensen submits: The bulls won Thursday’s session with one of the three biggest rallies so far in 2010.
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice